Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,605.62
(
1.52%
)
US TECH 100
23,621.20
(
1.46%
)
Dow Jones
46,377.10
(
1.75%
)
Brent Oil
95.85
(
-11.36%
)
Bitcoin
70,880.00
(
4.48%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: alia post# 3350

Monday, 04/23/2007 7:44:30 AM

Monday, April 23, 2007 7:44:30 AM

Post# of 19309
Re: Off-label ATryn

Some plasma-derived antithrombin products have a label that includes acquired deficiencies in certain European countries. Based on your information, Germany is presumably one of these countries.

Although it makes sense from a medical standpoint to substitute ATryn in any indication where a plasma-derived AT has been used, it unfortunately does not follow that ATryn will be reimbursed for use in an acquired antithrombin deficiency just because a plasma-derived antithrombin product has such a label. Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today